City
Epaper

Confident of meeting US govt standards, says supplier of Johnson and Johnson Covid-19 vaccine

By ANI | Updated: April 3, 2021 00:05 IST

Johnson and Johnson (J&J) vaccine supplier Emergent BioSolutions said in a statement that it acknowledges it botched a batch of vaccines but is confident of its ability to meet US government safety requirements and standards.

Open in App

Johnson and Johnson (J&J) vaccine supplier Emergent BioSolutions said in a statement that it acknowledges it botched a batch of vaccines but is confident of its ability to meet US government safety requirements and standards.

The statement comes a day after Johnson & Johnson reported on Wednesday that it found 15 million doses of vaccines to be unusable due to a human error in an Emergent Biosolutions' plant in the city of Baltimore, as reported by Sputnik.

"A single batch of drug substance was identified that did not meet specifications and our rigorous quality standards. We isolated this batch and it will be disposed of properly," the statement said on Thursday. "Discarding a batch of bulk drug substance, while disappointing, does occasionally happen during vaccine manufacturing, which is a complex and multi-step biological process."

"We are pleased we have met our commitment to deliver enough single-shot vaccines by the end of March to enable the full vaccination of more than 20 million people in the United States. This is part of our plan to deliver 100 million single-shot vaccines to the U.S. during the first half of 2021, aiming to deliver those doses by the end of May," the statement further read.

Emergent BioSolutions said in the statement it remains confident the requirements it will meet the safety requirements and standards of the Food and Drug Administration (FDA).

The Johnson & Johnson vaccine was approved for emergency use in the United States at the end of February, becoming the third vaccine to be authorized by the FDA in addition to the ones produced by Pfizer/BioNTech and Moderna.

On Wednesday, Johnson & Johnson said in a statement that it was still planning to supply 100 million doses by the end of May.

( With inputs from ANI )

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Tags: Johnson & JohnsonBaltimoreFood And Drug AdministrationUnited StatesThe statesFood products, medicinesUnited states food and drug administrationEuaCommissioner of food and drugs administrationUsfda
Open in App

Related Stories

OpinionsWhy is Trump So Upset with India?

MumbaiMumbai: Viral Video Shows Foreigner Mobbed for Selfies, Sparks Online Outcry Over Tourist Safety

EntertainmentAkshay Oberoi Set to Make His International Debut, The Actor Jets Off to the US

InternationalIndian Woman Caught Stealing Merchandise Worth Over INR 1 Lakh from US Store; Video Surfaces

MumbaiMumbai: FDA Suspends Caterers' License After MLA Sanjay Gaikwad Assaults Canteen Staff Over Food Quality

International Realted Stories

InternationalIndia's rise under PM Modi vs America's decline under Trump: TN BJP slams US tariff hike

InternationalTrump's tariffs take effect as US clocks strike midnight

InternationalForeign Secretary to visit Nepal to lay grounds for Nepal PM's visit to India

International"Don't want to get to a point where we hurt ourselves," White House on 50pc tariffs on India, China

InternationalGhanaian ministers among 8 killed in helicopter crash